Information on
this is also showing up elsewhere which suggests that this protocol is making
serious headway. I have grown weary of
the awful chemotherapy protocol which has never actually worked the way claimed
and has been grossly manipulated into the system. Seeing gthe end of that will be a
blessing.
Other
excellent protocols also exist but they all rely a lot on the patient changing
his lifestyle and many other proactive decisions. Some work out and many also do not.
This will
simply shut down the developing problem and clearly reset the clock and that is
more than enough.
Cancer
Drug That Shrinks All Tumors Set To Begin Human Clinical Trials
Researchers are one step
closer to uncovering a cancer treatment that could be applicable across the
board in killing every kind of cancer tumor.
After successful trials
in mice, the cancer drug that so far
has shrunk or cured all types of tumors it has been tested against will now move to human clinical trials, thanks to a $20
million grant.
A study published March
2012 discusses researchers' find that the one-for-all antibody drug
successfully blocks a specific protein, CD47, from tricking the
body's immune system into not destroying harmful cells. Though this protein is
present on the surface of healthy blood cells, the team from Stanford
University's School of Medicine determined that CD47 levels were significantly
higher in all cancer cells.
The single antibody
treatment works by blocking the protein's signal, thus instructing the body's
immune system to attack the cancer cells.
"What we've shown is
that CD47 isn't just important on leukemias and lymphomas," Stanford
Professor of Pathology and lead study author Dr. Irving Weissman told Science NOW, referring to his previous research that inspired the most
recent study. "It's on every single human primary tumor that we
tested."
After publishing their
findings in the Proceedings of the National Academy of Science, the team tested
the drug treatment on mice with seven different types of human cancer tumors --
breast, ovary, colon, bladder, brain, liver and prostate. By either killing or
shrinking each tumor, the innovative antibody drug prevented the cancer from
spreading to other parts of the body.
"Blocking this
‘don’t-eat-me’ signal inhibits the growth in mice of nearly every human cancer
we tested, with minimal toxicity," Weissman said in a
statement released by Stanford in 2012. "This shows conclusively
that this protein, CD47, is a legitimate and promising target for human cancer
therapy."
Funded by a four-year,
$20 million grant from the California
Institute for Regenerative Medicine, Weissman and his team will now prepare for
the first phase of human clinical trials.
No comments:
Post a Comment